Lessons from recent EU payer decisions on gene therapies
rgmarketaccessinsights.substack.com
Last Monday was another landmark day for gene therapies as a new and potentially curative one-off gene therapy for babies with spinal muscular atrophy (SMA) looks set to become the most expensive treatment ever recommended by NICE. So let’s take a closer look at the
Lessons from recent EU payer decisions on gene therapies
Lessons from recent EU payer decisions on…
Lessons from recent EU payer decisions on gene therapies
Last Monday was another landmark day for gene therapies as a new and potentially curative one-off gene therapy for babies with spinal muscular atrophy (SMA) looks set to become the most expensive treatment ever recommended by NICE. So let’s take a closer look at the